Van Camp Roscoe O
U.S. Air Force, MC, SFS, 4754 Munstead Woods Ct., Las Vegas, NV 89130-2358, USA.
Aviat Space Environ Med. 2009 Jun;80(6):553-5. doi: 10.3357/asem.2460.2009.
Zolpidem is a hypnotic medication approved to manage sleep for crewmembers involved in combat operations in the USAF and other services. Previous studies demonstrated the effectiveness of zolpidem under laboratory conditions, but confirmation from the field is needed.
We evaluated zolpidem in managing sleep-work cycles for crews of remotely piloted aircraft (RPA) during surge combat operations. There were 3 10-mg tablets of zolpidem dispensed to each of 43 crewmembers tasked to support RPA surge combat operations requiring rapid unscheduled shift changes. All personnel were required to take the drug on a non-flying day to evaluate its individual effect; use of the drug during operations was voluntary.
The surge operations were carried out successfully with no flight or ground mishaps. There were 27 crewmembers (63%) who used the medication. Of those, 19 reported that the intervention resulted in good sleep without side effects or morning drowsiness. The other eight subjects reported side effects consisting of drug hangover (N = 4) or poor sleep with frequent awakening (N = 4). There were no reports of abnormal sleep behaviors. Five crewmembers considered the medication essential to duty performance.
Zolpidem promoted the safe induction of sleep and was used successful by a majority of the RPA crewmembers. Side effects occurred in some crewmembers even though they had previously tested the drug without side effects. A small subset of the test group heavily relied on medication to successfully manage their sleep-rest cycle.
唑吡坦是一种催眠药物,已被批准用于管理美国空军及其他军种参与战斗行动的机组人员的睡眠。先前的研究在实验室条件下证明了唑吡坦的有效性,但仍需要来自实际应用场景的确认。
我们评估了唑吡坦在激增战斗行动期间对遥控飞机(RPA)机组人员睡眠-工作周期的管理效果。向43名负责支持需要快速非计划轮班变化的RPA激增战斗行动的机组人员每人分发了3片10毫克的唑吡坦。所有人员被要求在非飞行日服用该药物以评估其个体效果;行动期间使用该药物是自愿的。
激增行动成功进行,没有发生飞行或地面事故。有27名机组人员(63%)使用了该药物。其中,19人报告该干预措施带来了良好的睡眠,没有副作用或晨起嗜睡。其他8名受试者报告了副作用,包括药物宿醉(4人)或睡眠不佳且频繁醒来(4人)。没有关于异常睡眠行为的报告。5名机组人员认为该药物对履行职责至关重要。
唑吡坦促进了安全的睡眠诱导,并且大多数RPA机组人员成功使用了它。一些机组人员出现了副作用,尽管他们之前测试该药物时没有副作用。一小部分测试组人员严重依赖药物来成功管理他们的睡眠-休息周期。